Darou Darman Arang is a fast growing pharmaceutical Company in Iran.
Darou Darman Arang is a fast growing pharmaceutical Company in Iran.
We are a fast growing pharmaceutical company manufacturing our own brands and representing pharmaceutical companies from around the world in Iran to import medicines.
DAROU DARMAN ARANG acts as the representative agent for specialty, rare disease, biotech and vaccine producing companies looking to penetrate to Iran. We are the preferred strategic partner, providing turn-key solutions and support for their commercial operations…… Read more
We have ensured world-class quality in design, equipment and operations in our manufacturing facility. Our units ensure that we are able to provide best-in-class products to patients across the Iran and emerging markets around. Our manufacturing operations are focused on producing generics and branded generics, in the full range of dosage forms, including tablets, capsules, injectable, pre-filled syringe and freeze dried powder. …… Read more
Imports of Finished Pharmaceuticals
As the pioneer of our mission to meet the needs of the health society across IRAN and beyond with our expert staffs and facilities to import different health care products…… Read more
We in R&D department aimed to Reach to various market requirements and high quality products, by representing formulation and providing new method analysis, taking advantage of experienced Experts, using the most up to dated sources of pharmaceuticals and advanced devices. In addition to exploitation of cooperation and consultation of prominent University professors and other authentic science centers.
Read MoreRegulatory
Having sufficient knowledge of drug registration rules & regulations for registration of products
Adequately capability of registering new products in the Drug National List
Well knowledge of the drug, raw material and food supplement approval process and registration bureaucracy in Ministry of Health
Submitting registration documents to MOH
DAROU DARMAN ARANG COMPANY WAS ESTABLISHED BY A GROUP OF EXPERIENCED PEOPLE TO ATTRACT, DEVELOP AND DELIVER NEW CAPABILITIES.
<p>On 25 July and 27 June 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of marketing authorization for four ustekinumab biosimilars.</p>
<p>On 18 July 2024, it was announced that Boehringer Ingelheim (Boehringer) and GoodRx, the leading prescription savings platform in the US, launched a patient affordability initiative. From now on, Boehringer's citrate-free adalimumab-adbm, a biosimilar to Humira (adalimumab), will be available at a 92% discount to the list price of the AbbVie originator drug, exclusively on GoodRx.</p>
<p>In July 2024, it was announced that China’s Hasten Biopharmaceutical has acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Korea’s Celltrion.</p>
